Company CervoMed Inc.

Equities

CRVO

US15713L1098

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
24.7 USD +1.02% Intraday chart for CervoMed Inc. +1.23% +223.72%

Business Summary

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.

Number of employees: 8

Sales per Business

USD in Million2022Weight2023Weight Delta
Neurological Treatment
100.0 %
- - 7 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 7 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 62 23-08-15
Director of Finance/CFO 66 23-08-15
Chief Tech/Sci/R&D Officer 60 23-08-15
Chief Operating Officer 60 23-08-15
General Counsel 41 23-08-15

Members of the board

Members of the board TitleAgeSince
Chairman 72 Feb. 06
Chief Executive Officer 62 23-08-15
Director/Board Member 58 23-08-15
Director/Board Member 63 23-08-15
Director/Board Member 66 23-08-15
Chief Operating Officer 60 23-08-15
Director/Board Member 56 23-08-15
Director/Board Member 58 23-08-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 8,253,741 5,369,547 ( 65.06 %) 0 65.06 %

Shareholders

NameEquities%Valuation
John Alam
17.71 %
1,461,578 17.71 % 37 M $
1,057,268 12.81 % 26 M $
RA Capital Management LP
10.000 %
825,373 10.000 % 21 M $
Adage Capital Partners GP LLC
2.415 %
199,347 2.415 % 5 M $
Crown Advisors Management, Inc.
1.212 %
100,000 1.212 % 2 M $
CWM LLC
0.7159 %
59,088 0.7159 % 1 M $
Renaissance Technologies LLC
0.3724 %
30,733 0.3724 % 768 018 $
Vanguard Global Advisers LLC
0.3307 %
27,292 0.3307 % 682 027 $
BlackRock Institutional Trust Co. NA
0.2643 %
21,816 0.2643 % 545 182 $
Geode Capital Management LLC
0.2566 %
21,175 0.2566 % 529 163 $

Company contact information

CervoMed, Inc.

20 Park Plaza Suite 424

02216, Boston

+

http://www.cervomed.com
address CervoMed Inc.(CRVO)
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW